Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc (NQ: BEAM )

34.80 +0.86 (+2.53%)
Streaming Delayed Price Updated: 11:46 AM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
Beam Therapeutics to Participate in Upcoming May Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
The Ark Invest CEO is betting on rebounds for these beaten-down stocks. 
Via The Motley Fool
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics: Q1 Earnings Insights
 
Via Benzinga
Where Beam Therapeutics Stands With Analysts
 
Via Benzinga
Where Beam Therapeutics Stands With Analysts
 
Via Benzinga
Analyst Ratings for Beam Therapeutics
 
Via Benzinga
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
From Beam Therapeutics
Via GlobeNewswire
7 Best Cathie Wood Stocks for Your May 2023 Buy List
This year promises to be very different for Cathie Wood stocks, as signs of economic improvement become more prominent. 
Via InvestorPlace
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
Cathie Wood is loading up on these biotech stocks. 
Via The Motley Fool
The 3 Most Promising Gene Editing Stocks to Buy in 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in. 
Via InvestorPlace
Cathie Wood Is Unstoppable With Tesla Stock – Defies Wall Street To Make Whopping $29M Purchase
 
Via Benzinga
3 Stocks to Watch in April: Is it Time to Buy?
With several fundamental factors pushing against the equities sector, these stocks to watch in particular draw significant intrigue. 
Via InvestorPlace
7 Top Growth Stocks to Buy for the Next Decade
These Growth Stocks to Buy Don't Require a 10-year Horizon But Should be More Valuable Then 
Via InvestorPlace
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
 
Via Benzinga
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
From Beam Therapeutics
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
 
Via Benzinga
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on. 
Via InvestorPlace
3 Game-Changing Stocks to Buy in March
Innovation is in these companies' DNA. 
Via The Motley Fool
The Top 7 Growth Stocks in Biotech
The biotech sector always houses a great selection of growth stocks that can grow rapidly and reward investors over the long-term. 
Via InvestorPlace
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
Better Buy: Beam Therapeutics or Intellia Therapeutics?
The two clinical-stage gene-editing companies have good long-term prospects. 
Via The Motley Fool
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
From Beam Therapeutics
Via GlobeNewswire
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Cathie Wood is bullish about these stocks. And so are Wall Street analysts. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.